Please use this identifier to cite or link to this item:
https://doi.org/10.4049/jimmunol.1102343
DC Field | Value | |
---|---|---|
dc.title | Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression | |
dc.contributor.author | Zeng, J. | |
dc.contributor.author | Shahbazi, M. | |
dc.contributor.author | Wu, C. | |
dc.contributor.author | Toh, H.C. | |
dc.contributor.author | Wang, S. | |
dc.date.accessioned | 2014-10-27T08:27:28Z | |
dc.date.available | 2014-10-27T08:27:28Z | |
dc.date.issued | 2012-05-01 | |
dc.identifier.citation | Zeng, J., Shahbazi, M., Wu, C., Toh, H.C., Wang, S. (2012-05-01). Enhancing immunostimulatory function of human embryonic stem cell-derived dendritic cells by CD1d overexpression. Journal of Immunology 188 (9) : 4297-4304. ScholarBank@NUS Repository. https://doi.org/10.4049/jimmunol.1102343 | |
dc.identifier.issn | 00221767 | |
dc.identifier.uri | http://scholarbank.nus.edu.sg/handle/10635/100584 | |
dc.description.abstract | Human embryonic stem cell-derived dendritic cells (hESC-DCs) may potentially provide a platform to generate "off-the-shelf" therapeutic cancer vaccines. To apply hESC-DCs for cancer immunotherapy in a semiallogeneic setting, it is crucial for these cells to "jump-start" adaptive antitumor immunity before their elimination by host alloreaction. In this study, we investigated whether CD1d upregulation in hESC-DCs may exploit invariant NKT (iNKT) cell adjuvant activity and boost antitumor immunity. Using a baculoviral vector carrying the CD1d gene, we produced CD1d-overexpressing hESC-DCs and demonstrated that the upreg-ulated CD1d was functional in presenting α-galactosylceramide for iNKT cell expansion. Pulsed with melanoma Ag recognized by T cell 1 peptide, the CD1d-overexpressing hESC-DCs displayed enhanced capability to prime CD8 + T cells without relying on α-galactosylceramide loading. Blocking the CD1d with Ab reduced the immunogenicity, suggesting the importance of hESC-DC and iNKT cell interaction in this context. The CD1d-overexpressing hESC-DCs also induced a proinflammatory cytokine profile that may favor the T cell priming. Moreover, a similar immunostimulatory effect was observed when the CD1d upregulation strategy was applied in human monocyte-derived dendritic cells. Therefore, our study suggests that the upregulation of CD1d in hESC-DCs provides a novel strategy to enhance their immunogenicity. This approach holds potential for advancing the application of hESC-DCs into human cancer immunotherapy. © 2012 by The American Association of Immunologists, Inc. | |
dc.description.uri | http://libproxy1.nus.edu.sg/login?url=http://dx.doi.org/10.4049/jimmunol.1102343 | |
dc.source | Scopus | |
dc.type | Article | |
dc.contributor.department | BIOLOGICAL SCIENCES | |
dc.description.doi | 10.4049/jimmunol.1102343 | |
dc.description.sourcetitle | Journal of Immunology | |
dc.description.volume | 188 | |
dc.description.issue | 9 | |
dc.description.page | 4297-4304 | |
dc.description.coden | JOIMA | |
dc.identifier.isiut | 000303299900021 | |
Appears in Collections: | Staff Publications |
Show simple item record
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.